BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement (NCT07240493) | Clinical Trial Compass
CompletedNot Applicable
BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement
Iraq24 participantsStarted 2024-12-15
Plain-language summary
This randomized controlled clinical trial aims to evaluate the effect of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) on the stability and marginal bone level of dental implants following immediate placement.
patients requiring extraction of unrestorable tooth in upper incisors or premolar region will be randomly assigned into two groups: the experimental group will receive immediate implant placement with rhBMP-2 application, while the control group will receive immediate implant placement without rhBMP-2.
each group includes 16 immediate implants. Implant stability will be assessed using resonance frequency analysis (RFA) at baseline, and 16 weeks after implant placement. Marginal bone level changes will be evaluated radiographically using cone beam computed tomography (CBCT).
The study aims to determine whether the use of rhBMP-2 enhances osseointegration and reduces marginal bone loss compared with conventional immediate implant placement.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy patients ≥18 years of either sex
* Having a single or multiple unrestorable maxillary anterior and premolar teeth indicated for extraction
* Jumping gap ≥2 mm
* Apical bone ≥3 mm from the vertical structure beyond the apex
* Willing to comply with the study and provide informed consent
* Good oral hygiene
Exclusion Criteria:
* Active infection or inflammation in implant area
* Uncontrolled diabetes or coagulation disorders
* Immunocompromised patients
* Patients treated with bisphosphonate drugs
* Psychiatric problems
* Pregnant women
* Medical conditions affecting bone healing
* Clinical evidence of parafunctional habits
* Heavy smokers (≥20 cigarettes/day)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Implant Stability Quotient (ISQ) measured by Resonance Frequency Analysis
Timeframe: Baseline and 16 weeks after implant placement